Modern management of mild-to-moderate joint pain due to osteoarthritis: A holistic approach

Journal of International Medical Research

Volumn 38, Issue 4, 2010, Pages 1175-1212

  Huskisson, E C ^a  

^a KING EDWARD VII HOSPITAL   (United Kingdom)

Author keywords

Analgesics; Chondroitin; Glucosamine; Non steroidal anti inflammatory drugs; Nutraceuticals; Osteoarthritis; Pain relief

Indexed keywords

ASCORBIC ACID; CELECOXIB; CHONDROITIN; CHONDROITIN SULFATE; DICLOFENAC; DICLOFENAC DIETHYLAMINE; DICLOFENAC POTASSIUM; DIMETHYL SULFOXIDE; GLUCOSAMINE; HOMEOPATHIC AGENT; IBUPROFEN; INDOMETACIN; KETOPROFEN; MANGANESE ASCORBATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENNSAID; PIROXICAM; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ANGIONEUROTIC EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE REACTION; ARTHRALGIA; ASTHMA; BURNING SENSATION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CREATININE CLEARANCE; DIARRHEA; DIET THERAPY; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EPIGASTRIC PAIN; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HALITOSIS; HEADACHE; HEARTBURN; HIRSUTISM; HUMAN; INTERMETHOD COMPARISON; KINESIOTHERAPY; KNEE OSTEOARTHRITIS; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MUSCLE CRAMP; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PATIENT ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT SELECTION; PHOTOALLERGY; PHOTOSENSITIVITY; PHOTOTOXICITY; PRACTICE GUIDELINE; PRURITUS; PYELONEPHRITIS; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SKIN DISCOLORATION; SKIN MANIFESTATION; TASTE DISORDER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 77957735866     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800401     Document Type: Review

References (117)

1. Edwards J: Rheumatology. Joints and connective tissue: introduction. In: Oxford Textbook of Medicine, Vol 3, 4th edn (Warrell D, Cox T, Firth J, eds). Oxford: Oxford University Press, 2003; pp 3-11.
2. Brion P, Kalunian K: Rheumatology. Osteoarthritis. In: Oxford Textbook of Medicine, Volume 3, 4th edn (Warrell D, Cox T, Firth J, eds). Oxford: Oxford University Press, 2003; pp 62-68.
3. Altman R, Lozada C: Osteoarthritis and related disorders. Clinical features. In: Practical Rheumatology, 3rd edn (Hochberg M, Silman A, Smolen J, et al, eds). Philadelphia: Elsevier, 2004; pp 503-510.
4. Felson D: An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin North Am 2004; 42: 1-9.
5. Gordon D, Hastings D: Clinical features of rheumatoid arthritis. In: Practical Rheumatology, 3rd edn (Hochberg M, Silman A, Smolen J, et al, eds). Philadelphia: Elsevier, 2004; pp 285-300.
6. Hunter D, Lo G: The management of osteoarthritis: an overview and call to appropriate conservative treatment. Rheum Dis Clin North Am 2008; 34: 689-712.
7. Jordan K, Sawyer S, Coakley P, et al: The use of conventional and complementary treatments for knee osteoarthritis in the community. Rheumatology (Oxford) 2003; 43: 381-384.
8. Arden N, Nevitt M: Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006; 20: 3-25.
9. Jordan K, Arden N, Doherty M, et al: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-1155.
10. Zhang W, Moskowitz RW, Nuki G, et al: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-162.
11. National Institute for Clinical Excellence (NICE): Osteoarthritis. The care and management of osteoarthritis in adults. NICE Clinical Guideline London: NICE, 2008; p 3.
12. Pendleton A, Arden N, Dougados M, et al: EULAR recommendations for the management of knee osteoarthritis. Ann Rheum Dis 2000; 59: 936-944.
13. Lozada CJ, Altman RD: Management of limb joint osteoarthritis. In: Practical Rheumatology, 3rd edn (Hochberg M, Silman A, Smolen J, et al, eds). Philadelphia: Elsevier, 2004; pp 511-519.
14. American College of Rheumatology: ACR Drafts Treatment Guidelines for Knee, Hip, and Hand Osteoarthritis. 2009 (available at: http://www.medscape.com/viewarticle/711171?sssdmh=dm1552196&src=confwrap&uac=117734DN).
15. Christensen R, Astrup A, Bliddal H: Weight loss: the treatment of choice for knee osteoarthritis? A randomized trial. Osteoarthritis Cartilage 2005; 13: 20-27.
16. Messier S, Loeser R, Miller G, et al: Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the arthritis, diet and activity promotion trial. Arthritis Rheum 2004; 50: 1501-1510.
17. Deyle G, Allison S, Matekel R, et al: Physical therapy treatment effectiveness for osteoarthritis of the knee: a randomized comparison of supervised clinical exercise and manual therapy procedures versus a home exercise program. Phys Ther 2005; 85: 1301-1317.
18. Huskisson EC: Glucosamine and chondroitin for osteoarthritis. J Int Med Res 2008; 36: 1161-1179.
19. Thie NM, Prasad NG, Major PW: Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. J Rheumatol 2001; 28: 1347-1355.
20. Qiu G, Gao S, Giacovelli G, et al: Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung 1998; 48: 469-474.
21. Müller-Fassbender H, Bach G, Haase W, et al: Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 61-69.
22. Lopes Vaz A: Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin 1982; 8: 145-149.
23. Lippiello L, Woodward J, Karpman R, et al: In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop 2000; 381: 229-240.
24. Kelly GS: The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern Med Rev 1998; 3: 27-39.
25. Deal CL, Moskowitz RW: Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 1999; 25: 379-395.
26. Setnikar I, Giacchetti C, Zanolo G: Pharmacokinetics of glucosamine in the dog and in man. Arzneimittelforschung 1986; 36: 729-735.
27. Barclay T, Tsourounis C, McCart G: Glucosamine. Ann Pharmacother 1998; 32: 574-579.
28. Persiani S, Rotini R, Trisolino G, et al: Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulfate at therapeutic dose. Osteoarthritis Cartilage 2007; 15: 764-772.
29. Conte A, Volpi N, Palmieri L, et al: Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung 1995; 45: 918-925.
30. Simánek V, Kren V, Ulrichová J, et al: The efficacy of glucosamine and chondroitin sulfate in the treatment of osteoarthritis: are these saccharides drugs or nutraceuticals? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149: 51-56.
31. Clegg D, Reda D, Harris C, et al: Glucosamine, chondroitin sulphate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795-808.
32. Leffler C, Philippi A, Leffler S, et al: Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med 1999; 164: 85-91.
33. Das A JR, Hammad T: Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage 2000; 8: 343-350.
34. Cohen M, Wolfe R, Mai T, et al: A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 2003; 30: 523-528.
35. Bruyere O, Pavelka K, Rovati LC, et al: Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 2004; 11: 134-135.
36. Crolle G, D'Este E: Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 1980; 7: 104-109.
37. Dodge GR, Hawkins DF, Jimenez SA: Modulation of aggrecan, MMPI and MMP3 production by glucosamine sulfate in cultured human osteoarthritis articular chondrocytes. Arthritis Rheum 1999; 42(suppl): 253.
38. Drovanti A, Bignamini AA, Rovati AL: Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled doubleblind investigation. Clin Ther 1980; 3: 260-272.
39. Houpt J, McMillan R, Wein C, et al: Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999; 26: 2423-2430.
40. Noack W, Fischer M, Förster KK, et al: Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 51-59.
41. Pavelka K, Gatterova J, Olejarova M, et al: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113-2123.
42. Pujalte JM, Llavore EP, Ylescupidez FR: Doubleblind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980; 7: 110-114.
43. Reginster JY, Deroisy R, Rovarti LC, et al: Longterm effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-256.
44. Reichelt A, Förster KK, Fischer M, et al: Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. Arzneimittelforschung 1994; 44: 75-80.
45. Talent JM, Gracy RW: Pilot study of oral polymeric N-acetyl-D-glucosamine as a potential treatment for patients with osteoarthritis. Clin Ther 1996; 18: 1184-1190.
46. Tapadinhas MJ, Rivera IC, Bignamini AA: Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica 1982; 3: 157-168.
47. Vajaradul Y: Double-blind clinical evaluation of intra-articular glucosamine in outpatients with gonarthrosis. Clin Ther 1981; 3: 336-343.
48. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al: Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007; 56: 555-567.
49. Hochberg M, Clegg D: Potential effects of chondroitin sulfate on joint swelling: a GAIT report. Osteoarthritis Cartilage 2008; 16(suppl 3): S22-S24.
50. Richy F, Bruyere O, Ethgen O, et al: Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514-1522.
51. Towheed T, Maxwell L, Anastassiades TP, et al: Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: CD002946.
52. Cohen J: Statistical Power Analysis for the Behavioural Sciences. New York: Academic Press, 1977.
53. Christgau S, Henroitin Y, Tanko LB, et al: Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 2004; 22: 36-42.
54. Altman RD, Abadie E, Avouac B, et al: Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoporosis. Osteoarthritis Cartilage 2005; 13: 13-19.
55. Poolsup N, Suthisisang C, Channark P, et al: Long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother 2005; 39: 1080-1087.
56. Sawitzke A, Shi H, Finco M, et al: The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008; 58: 3183-3191.
57. Owens S, Wagner P, Vangsness CT: Recent advances in glucosamine and chondroitin supplementation. J Knee Surg 2004; 17: 185-193.
58. Alekseeva LI, Mednikov BL, Piiavskï SA, et al: Pharmacoeconomic aspects of use of structum in osteoarthrosis. Ter Arkh 2001; 73: 90-92 [in Russian].
59. Bourgeois P, Chales G, Dehais J, et al: Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage 1998; 6(suppl A): 25-30.
60. Bucsi L, Poor G: Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slowacting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998; 6(suppl A): 31-36.
61. Leeb BF, Schweitzer H, Montag K, et al: A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205-211.
62. Mazieres B, Hucher M, Zaïm M, et al: Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2007; 66: 639-645.
63. Morreale P, Manopulo R, Galati M, et al: Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996; 23: 1385-1391.
64. Uebelhart D, Malaise M, Marcolongo R: Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004; 12: 269-276.
65. Verbruggen G, Goemaere S, Veys EM: Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002; 21: 231-243.
66. Uebelhart D, Thonar EJ, Delmas PD, et al: Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998; 6(suppl A): 39-46.
67. Michel BA, Stucki G, Frey D, et al: Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005; 52: 779-786.
68. Tannis AJ, Barban J, Conquer JA: Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage 2004; 12: 506-511.
69. Scroggie DA, Albright A, Harris MD: The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebocontrolled, double-blinded, randomized clinical trial. Arch Intern Med 2003; 163: 1587-1590.
70. Danao-Camara T: Potential side effects of treatment with glucosamine and chondroitin. Arthritis Rheum 2000; 43: 2853.
71. Tallia A, Cardone D: Asthma exacerbation associated with glucosamine-chondroitin supplement. J Am Board Fam Pract 2002; 15: 481-484.
72. Lin J, Zhang W, Jones A, et al: Efficacy of topical NSAIDs in the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. BMJ 2004; 329: 324.
73. Altman R, Barkin R: Topical therapy for osteoarthritis: clinical and pharmacological perspectives. Postgrad Med 2009; 121: 139-147.
74. Cordero J, Camacho M, Obach R, et al: In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs. Eur J Pharm Biopharm 2001; 51: 135-142.
75. Cordero JA, Alarcon L, Escribano E: A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs. J Pharm Sci 1997; 86: 503-508.
76. Singh P, Roberts MS: Skin permeability and local tissue concentrations of non-steroidal anti-inflammatory drugs after topical application. J Pharm Exp Ther 1994; 268: 144-151.
77. Zacher J, Altman R, Bellamy N, et al: Topical diclofenac and its role in pain and inflammation: an evidence-based review. Curr Med Res Opin 2008; 24: 925-950.
78. Riess W, Schmid K, Botta L, et al: The percutaneous absorption of diclofenac. Arzneimittelforschung 1986; 36: 1092-1096 [in German].
79. Dreiser RL: Topical antirheumatic drug therapy: current practice and future trends. Eur J Rheumatol Inflamm 1994; 14: 3-8.
80. Sioufi A, Pommier F, Boschet F, et al: Percutaneous absorption of diclofenac in healthy volunteers after single and repeated topical application of diclofenac Emulgel. Biopharm Drug Dispos 1994; 15: 441-449.
81. Brune K: Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability. Curr Med Res Opin 2007; 23: 2985-2995.
82. Radermacher J, Jentsch D, Scholl MA, et al: Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol 1991; 31: 537-541.
83. Davies NM, Anderson KE: Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33: 184-213.
84. Magnusson BM, Anissimov YG, Cross SE, et al: Molecular size as the main determinant of solute maximum flux across the skin. J Invest Dermatol 2004; 122: 993-999.
85. Hewitt P, Poblete N, Wester R, et al: In vitro cutaneous disposition of a topical diclofenac lotion in human skin: effect of a multi-dose regimen. Pharm Res 1998; 15: 988-992.
86. Hui X, Hewitt P, Poblete N, et al: In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm Res 1998; 15: 1589-1595.
87. Brunner M, Dehghanyar P, Seigfried B, et al: Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. Br J Clin Pharmacol 2005; 60: 573-577.
88. Kienzler J, Gold M, Nollevaux F: Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol 2010; 50: 50-61.
89. Muller M, Mascher H, Kikuta C, et al: Diclofenac concentrations in defined tissue layers after topical administration. Clin Pharmacol Ther 1997; 62: 293-299.
90. Banning M: Topical diclofenac: clinical effectiveness and current uses in osteoarthritis of the knee and soft tissue injuries. Exp Opin Pharmacother 2008; 9: 2921-2929.
91. Niethard FU, Gold MS, Solomon GS, et al: Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol 2005; 32: 2384-2392.
92. Baer PA, Thomas LM, Shainhouse Z: Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Dis 2005; 6: 44.
93. Bookman AAM, Williams KSA, Shainhouse JZ: Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 2004; 171: 333-338.
94. Roth SH, Shainhouse JZ: Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004; 164: 2017-2023
95. Tugwell PS, Wells GA, Shainhouse JZ: Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004; 31: 2002-2012.
96. Bruhlmann P, Michel BA: Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial. Clin Exp Rheumatol 2003; 21: 193-198.
97. Zacher J, Burger KJ, Färber L, et al: Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden's and/or Bouchard's nodes). Double-blind, controlled, randomized study. Akt Rheumatol 2001; 26: 7-14 [in German].
98. Grace D, Rogers J, Skeith K, et al: Topical diclofenac versus placebo: a double blind, randomised clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999; 26: 2659-2663.
99. Dreiser RL, Tisne-Camus M: DHEP plasters as a topical treatment of knee osteoarthritis-a double-blind placebo-controlled study. Drugs Exp Clin Res 1993; 19: 117-123.
100. Koenen NJ, Haag RF, Bias P, et al: Percutaneous therapy of activated osteoarthritis of the knee-comparison between DMSO and diclofenac. Munch Med Wochenschr 1996; 138: 534-538 [in German].
101. Widrig R, Suter A, Saller R, et al: Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. Rheumatol Int 2007; 27: 585-591.
102. Trnavský K, Fischer M, Vögtle-Junkert U, et al: Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis. Results of a randomized, double-blind, placebo-controlled study. J Rheumatol 2004; 31: 565-572.
103. Rovenský J, Miceková D, Gubzová Z, et al: Treatment of knee osteoarthritis with a topical non-steroidal antiinflammatory drug. Results of a randomized, double-blind, placebocontrolled study on the efficacy and safety of a 5% ibuprofen cream. Drugs Exp Clin Res 2001; 27: 209-221.
104. Balthazar-Letawe D: Voltaren Emugel in clinical rheumatology. Comparative trial with Indocid gel. Acta Belg Med Phys 1987; 10: 109-110 [in French].
105. van Haselen RA, Fisher PA: A randomized controlled trial comparing topical piroxicam gel with a homeopathic gel in osteoarthritis of the knee. Rheumatology (Oxford) 2000; 39: 714-719.
106. Rau R, Höckel S: Piroxicam gel versus diclofenac gel in activated gonarthrosis. Fortschr Med 1989; 107: 485-488 [in German].
107. Browning RC, Johson K: Reducing the dose of oral NSAIDs by use of Feldene Gel: an open study in elderly patients with osteoarthritis. Adv Ther 1994; 77: 198-207.
108. Waikakul S, Penkitti P, Soparat K, et al: Topical analgesics for knee arthrosis: a parallel study of ketoprofen gel and diclofenac emulgel. J Med Assoc Thai 1997; 80: 593-597.
109. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS): Suspension de L'AMM des gels de kætoprofène. Lettres aux professionels de santé, 18 December 2009 (available at http://www.afssaps.fr/Infos-desecurite/Lettres-aux-professionnels-de-sante [in French]).
110. Saal JG: Zur perkutanen applikation von diclofenac: ergebnisse einer prospektiven studie bei 13113 patienten. Rheumatologie 1990; 10: 166-169 [in German].
111. British National Formulary 2009; 58, section 10.1.1, p 562.
112. Simon L, Grierson L, Naseer Z, et al: Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009; 143: 238-245.
113. Bjordal JM, Ljunggren AE, Klovning A, et al: Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004; 329: 1317.
114. Altman RD, Kuritzky L, Ruoff G: Improving long-term management of osteoarthritis. J Fam Pract 2009; 58(suppl 2): S17-S24.
115. Moore N: Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever. A review of its pharmacology, clinical efficacy and safety. Clin Drug Invest 2007; 27: 163-195.
116. Dreiser RL, Marty M, Ionescu E, et al: Relief of acute low back pain with diclofenac-K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo-controlled trial. Int J Clin Pharmacol Ther 2003; 41: 375-385.
117. Hasford J, Moore N, Hoye K: Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community based pharmacy setting. Int J Clin Pharmacol Ther 2004; 42: 415-422.